衰弱对癌症患者治疗相关临床结局影响的范围综述OA

Objective To examine the impact of frailty on treatment-related clinical outcomes in cancer patients,and to provide a theoretical basis for interventions targeting frailty in this population.Methods This scoping review was conducted in accordance with the Joanna Briggs Institute(JBI)framework,with the research question defined using the PCC(population,concept,and context)strategy.PubMed,Web of Science,Embase,CINAHL,and the Chinese databases CNKI,Wanfang,and SinoMed were systematically searched for studies on the impact of frailty on treatment-related clinical outcomes in cancer patients,with a retrieval time spanning from data-base inception to March 25,2025.Two reviewers independently screened the literature and extracted data.The extracted information included study design,cancer type/treatment modality,frailty assessment tools and timing,frailty prevalence,and treatment-related clinical outcomes.The included evidence was summarized descriptively.Results Twenty-seven studies were included.Frailty preva-lence ranged from 3.6%to 70.6%,with substantial variation across cancer types,assessment tools,and assessment time points.Existing evidence indicated that frailty was associated with adverse outcomes,including postoperative complications and hospitalization-related outcomes,mortality/survival outcomes,chemotherapy toxicity or treatment tolerance,and diminished quality of life and functional decline.Conclusion Frailty prevalence among cancer patients varies widely and is associated with multiple categories of treatment-related adverse outcomes.Frailty screening and risk-stratified management are recommended during the perioperative period and key phases of systemic therapy.However,due to heterogeneity in assessment tools and populations,further high-quality longitudinal studies are needed to validate its predictive value and to determine optimal assessment strategies.